Literature DB >> 8042231

Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy. A protocol with significant clinical potential.

A Bushell1, P J Morris, K J Wood.   

Abstract

Previous work from this laboratory has shown that donor-specific tolerance can be achieved in a mouse heart model if recipients are pretreated with a donor-specific blood transfusion (DST) in combination with a depleting anti-CD4 antibody. The advantage of this approach instead of simply using the antibody alone at the time of transplantation is that the nonspecific immunosuppressive effects of the antibody have largely decayed by the time of transplant such that donor-specific, rather than total, unresponsiveness results. However, this approach would not be applicable to clinical cadaveric transplantation since donor-specific transfusion at a specified time before transplant would not be possible. In an attempt to address these problems we have sought to determine (A) whether the state of unresponsiveness established by the anti-CD4/DST protocol could be maintained by repeated exposure only to the tolerizing antigen; (B) whether unrelated or random transfusion (RT) could substitute for DST in the anti-CD4/antigen pretreatment protocol, and (C) whether these two approaches could be successfully combined to provide an "umbrella unresponsiveness" that could be maintained until the time of transplant. Our data show, first, that antigen rechallenge without further antibody treatment can maintain a state of unresponsiveness to alloantigen; second, that random blood transfusion given under the cover of anti-CD4 monoclonal antibody leads to indefinite allograft survival and true tolerance in the long-term; and third, that once established by random transfusion under anti-CD4 cover, unresponsiveness can be maintained for an extended period by random transfusion alone. These results suggest that random blood transfusion combined with anti-CD4 monoclonal antibody therapy might be considered as a possible approach to the induction of specific unresponsiveness in clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042231

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Immunologic tolerance in renal transplantation.

Authors:  D A Shoskes
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 2.  T cell tolerance induced by therapeutic antibodies.

Authors:  Stephen P Cobbold
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

3.  Rapid dendritic cell activation and resistance to allotolerance induction in anti-CD154-treated mice receiving CD47-deficient donor-specific transfusion.

Authors:  Yuantao Wang; Hui Wang; Roderick Bronson; Yaowen Fu; Yong-Guang Yang
Journal:  Cell Transplant       Date:  2013-01-02       Impact factor: 4.064

4.  GITR Blockade Facilitates Treg Mediated Allograft Survival.

Authors:  Samsher B Sonawane; James I Kim; Major K Lee; Seoung-Hoon Lee; Patrick E Duff; Daniel J Moore; Moh-Moh Lian; Shaoping Deng; Yongwon Choi; Heidi Yeh; Andrew J Caton; James F Markmann
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

5.  Translating tolerogenic therapies to the clinic - where do we stand?

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

Review 6.  Regulatory T cells as immunotherapy.

Authors:  Benjamin D Singer; Landon S King; Franco R D'Alessio
Journal:  Front Immunol       Date:  2014-02-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.